Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathan D Seligson

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
JAMA Network Open|October 3, 2019
Common Secondary Genomic Variants Associated With Advanced Epithelioid HemangioendotheliomaNathan D Seligson, Achal Awasthi, Sherri Z Millis, et al.
Pharmacogenomics|September 13, 2023
Integrating pharmacogenomic testing into paired germline and somatic genomic testing in patients with cancerNathan D Seligson, Jill M Kolesar, Benish Alam, et al.
Translational Oncology|October 5, 2023
Gene partners of the EWSR1 fusion may represent molecularly distinct entitiesVictoria Walker, Dexter X Jin, Sherri Z Millis, et al.
The Oncologist|December 14, 2018
<i>BRCA1/2</i> Functional Loss Defines a Targetable Subset in LeiomyosarcomaNathan D Seligson, Esko A Kautto, Edward N Passen, et al.
NPJ Precision Oncology|April 26, 2022
Drivers of genomic loss of heterozygosity in leiomyosarcoma are distinct from carcinomasNathan D Seligson, Joy Tang, Dexter X Jin, et al.
Frontiers in Pharmacology|January 23, 2024
<i>CYP3A5</i> influences oral tacrolimus pharmacokinetics and timing of acute kidney injury following allogeneic hematopoietic stem cell transplantationNathan D Seligson, Xunjie Zhang, Mark C Zemanek, et al.
Pharmacogenomics|July 29, 2025
From bench to bedside: a spotlight on pharmacogenomics at Nemours Children's HealthKelsey J Cook, Nathan D Seligson, Benjamin Q Duong, et al.
Cancers|November 9, 2024
Correction: Nelson et al. <i>UGT1A1</i> Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. <i>Cancers</i> 2021, <i>13</i>, 1566Ryan S Nelson, Nathan D Seligson, Sal Bottiglieri, et al.
Cancers|April 3, 2021
<i>UGT1A1</i> Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical ImplementationRyan S Nelson, Nathan D Seligson, Sal Bottiglieri, et al.
Haematologica|March 2, 2023
<i>PARP1</i> and <i>POLD2</i> as prognostic biomarkers for multiple myeloma in autologous stem cell transplantMelissa Thomas, Junan Li, Kevan King, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
JAMA Network Open|October 3, 2019
Common Secondary Genomic Variants Associated With Advanced Epithelioid HemangioendotheliomaNathan D Seligson, Achal Awasthi, Sherri Z Millis, et al.
Pharmacogenomics|September 13, 2023
Integrating pharmacogenomic testing into paired germline and somatic genomic testing in patients with cancerNathan D Seligson, Jill M Kolesar, Benish Alam, et al.
Translational Oncology|October 5, 2023
Gene partners of the EWSR1 fusion may represent molecularly distinct entitiesVictoria Walker, Dexter X Jin, Sherri Z Millis, et al.
The Oncologist|December 14, 2018
<i>BRCA1/2</i> Functional Loss Defines a Targetable Subset in LeiomyosarcomaNathan D Seligson, Esko A Kautto, Edward N Passen, et al.
NPJ Precision Oncology|April 26, 2022
Drivers of genomic loss of heterozygosity in leiomyosarcoma are distinct from carcinomasNathan D Seligson, Joy Tang, Dexter X Jin, et al.
Frontiers in Pharmacology|January 23, 2024
<i>CYP3A5</i> influences oral tacrolimus pharmacokinetics and timing of acute kidney injury following allogeneic hematopoietic stem cell transplantationNathan D Seligson, Xunjie Zhang, Mark C Zemanek, et al.
Pharmacogenomics|July 29, 2025
From bench to bedside: a spotlight on pharmacogenomics at Nemours Children's HealthKelsey J Cook, Nathan D Seligson, Benjamin Q Duong, et al.
Cancers|November 9, 2024
Correction: Nelson et al. <i>UGT1A1</i> Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. <i>Cancers</i> 2021, <i>13</i>, 1566Ryan S Nelson, Nathan D Seligson, Sal Bottiglieri, et al.
Cancers|April 3, 2021
<i>UGT1A1</i> Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical ImplementationRyan S Nelson, Nathan D Seligson, Sal Bottiglieri, et al.
Haematologica|March 2, 2023
<i>PARP1</i> and <i>POLD2</i> as prognostic biomarkers for multiple myeloma in autologous stem cell transplantMelissa Thomas, Junan Li, Kevan King, et al.
Pageof 4